Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL
Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a combination therapy regimen for DLBCL that combines chemotherapy drugs with rituximab). Polatuzumab vedotin is an antibody-drug conjugate (ADC) used to treat DLBCL, both in first-line treatment and for relapsed or refractory cases.
At the 2025 World ADC London conference, WuXi Biology presented a poster examining the potential of polatuzumab vedotin as a therapeutic agent across a panel of established, in-house, DLBCL patient-derived xenograft (PDX) models. The authors show that a single dose of polatuzumab vedotin at just 2 mg/kg could reach a comparable effect with R-CHOP. Among the 8 lymphoma PDX models tested, 50% of them were shown to be sensitive to polatuzumab vedotin treatment.
Poster_World ADC London Conference 2025_Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL
Related Content
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....
VIEW RESOURCEAntibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency...
VIEW RESOURCE